Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Mucommune LLC has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. The busiest examiner for this company is PETRASH, HILARY ANN, who is responsible for 1 pending action. The portfolio's prosecution is currently limited to 1 distinct examiner and 1 distinct art unit. This indicates that the 1 pending office action represents the company's entire active workload at the USPTO.
Practitioners should note that the 1 distinct examiner in the Biotechnology & Pharmaceuticals area holds all current responsibility for the company's pending outcomes. The concentration in 1 distinct art unit suggests that the technical scope of the filings is very specific. Because there is only 1 pending office action, the practitioner's strategy should be highly focused on the 1 distinct examiner's past rulings and the procedural norms of the 1 distinct art unit. This centralized prosecution environment means that the 1 pending action will be the sole determinant of the company's immediate success in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PETRASH, HILARY ANN | 1 | 65.6% | +50.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17278217 | SYNTHETIC BINDING AGENTS FOR LIMITING PERMEATION THROUGH MUCUS | PETRASH, HILARY ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17278217 | SYNTHETIC BINDING AGENTS FOR LIMITING PERMEATION THROUGH MUCUS | PETRASH, HILARY ANN | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17278217 | SYNTHETIC BINDING AGENTS FOR LIMITING PERMEATION THROUGH MUCUS | PETRASH, HILARY ANN | 1644 | §103§112Other | Non-Final OA | — | Pending | Mar 19, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMucommune LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Hilary Ann Petrash has the most, with 1 of Mucommune LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
